TLR9 and cancer: To determine whether this TLR9 ligand-induced up regulation of IDO expression additionally activates CD4 IDO-specific T cells, PBMC from three cancer patients were treated with the TLR9 ligand CpG ODN in the presence of IL-2 for 14 days and, subsequently, examined for IDO-specific T cells.